

## FAST FACTS

# DERMABOND ADVANCED<sup>®</sup> Topical Skin Adhesive vs Liquiband<sup>®</sup> Exceed<sup>™</sup>

Advanced Medical Solutions (AMS) markets Liquiband<sup>®</sup> Exceed<sup>™</sup>, a topical skin adhesive (TSA) promoted as an equivalent to DERMABOND ADVANCED<sup>®</sup> Topical Skin Adhesive. However, **the formulations and supporting clinical evidence for these products are not equal.**

**DERMABOND<sup>®</sup> delivers consistent results from the brand you trust.**



## Formulation

### Liquiband<sup>®</sup> Exceed<sup>™</sup> Statement

Liquiband<sup>®</sup> Exceed<sup>™</sup> uses a 2-octyl cyanoacrylate (2-OCA) monomer, but does not include an initiator or thickener.<sup>1</sup>

### DERMABOND<sup>®</sup> Response

- In addition to a highly purified 2-OCA, DERMABOND<sup>®</sup> is developed with specific ratios of an initiator, stabilizer, and additives, that together, provide strong, flexible closure with microbial barrier protection that set it apart from the competition<sup>2-4</sup>



## Strength

### Liquiband<sup>®</sup> Exceed<sup>™</sup> Statement

AMS States that Liquiband<sup>®</sup> Exceed<sup>™</sup> provides similar strength to DERMABOND ADVANCED Adhesive while using less adhesive.<sup>1</sup>

### DERMABOND<sup>®</sup> Response

- DERMABOND ADVANCED Adhesive showed greater wound-bursting strength with 431.2 mmHg vs >250 mmHg for Liquiband<sup>®</sup> Exceed<sup>™</sup>.<sup>1,5\*</sup>
- DERMABOND ADVANCED Adhesive displayed greater tensile strength with 10.13 lbf vs. 6.40 lbf for Liquiband<sup>®</sup> Exceed<sup>™</sup>.<sup>6,7\*</sup>
- When used in addition to sutures, DERMABOND ADVANCED Adhesive was shown ex vivo to add 75% more strength to the wound closure than sutures alone<sup>8</sup>



## Protection

### Liquiband<sup>®</sup> Exceed<sup>™</sup> Statement

AMS claims Liquiband<sup>®</sup> Exceed<sup>™</sup> provides a microbial barrier that allows for the wound healing process to generate a natural microbial barrier at 48-72 hours after closure.<sup>1</sup>

### DERMABOND<sup>®</sup> Response

- Limited data is available to support LiquiBand<sup>®</sup> Exceed<sup>™</sup>'s microbial barrier claims. One study used as support is data on file (unavailable to the public), while the other study demonstrates the efficacy of DERMABOND<sup>®</sup>—not LiquiBand<sup>®</sup> Exceed<sup>™</sup>.<sup>9,10</sup>
- DERMABOND ADVANCED Adhesive provides 99% protection in vitro for 72 hours against organisms commonly responsible for surgical site infections<sup>3</sup>



## Evidence

### Liquiband<sup>®</sup> Exceed<sup>™</sup> Statement

There are 0 published randomized controlled trials (RCTs) for Liquiband<sup>®</sup> Exceed<sup>™</sup>.<sup>†</sup>

### DERMABOND<sup>®</sup> Response

- DERMABOND ADVANCED Adhesive and DERMABOND Adhesive are supported by 53 published RCTs evaluating 5,838 patients, and have more clinical experience, outcomes data and publications than any other TSA.<sup>††</sup>

**There are many TSAs to choose from, but only the DERMABOND Portfolio has been trusted for over 20 years and backed by a breadth of clinical data no other TSA can match!<sup>††</sup>**

\*Demonstrated in separate studies.


†Based on published literature in PubMed and SCOPUS, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.

††DERMABOND ADVANCED Adhesive tests equivalent or superior to DERMABOND Adhesive in head-to-head testing for microbial barrier, wound-bursting strength, tensile strength, flexibility, durability, viscosity, drying time, water vapor transmission rate, water resistance, and physician satisfaction.

Third-party trademarks used herein are trademarks of their respective owners.

## Why Choose the DERMABOND® Difference

DERMABOND ADVANCED® Topical Skin Adhesive has a formulation unlike any other TSA. In addition to a highly purified 2-OCA monomer, DERMABOND® is developed with specific ratios of an initiator and additives, that together, provide **strong, flexible closure with microbial barrier protection** that set it apart from Liquiband® Exceed™.<sup>2-4</sup>



## Choose the Right DERMABOND® for You

### DERMABOND ADVANCED® Topical Skin Adhesive

Trusted quality and proven efficacy for mid-to-large incisions—up to 15 cm in length<sup>3,11</sup>



### DERMABOND® Mini Topical Skin Adhesive

Proprietary DERMABOND® formulation in an economically efficient size for small incisions—up to 4 cm in length



### DERMABOND® PRINEO® Skin Closure System

Greater skin holding strength than skin sutures and staples in 22 - 60 cm sizes for longer, open incisions<sup>14</sup>



\*In wounds approximated with deep dermal sutures

**For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.**

**References:** 1. Alarcon J, Miller G. Liquiband® Exceed™ Topical Skin Adhesive summary of effectiveness data. Advanced Medical Solutions (Plymouth) Ltd; 2018. 2. Bhende S. Ethicon Notebook 4203: 45-48. May 9, 2011. Ethicon, Inc. 3. Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of DERMABOND® Topical Skin Adhesive. *Surg Infect (Larchmt)*. 2002;3:25-257. 4. U.S. Food & Drug Administration. DERMABOND® NX Topical Skin Adhesive Approval Letter. May 4, 2010. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/K100423.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100423.pdf). Accessed October 11, 2018. 5. Perry, L. Biomechanical evaluation of acute in-vivo incision wound closure strength of topical skin adhesives in the swine model. Report ETH35. August 1, 2011. Ethicon, Inc. 6. Keplinger, S. Performance evaluation of DERMABOND® NX Topical Skin Adhesive. Report O9PD070. January 15, 2010. Ethicon, Inc. 7. Kumar A. AST\_2015\_0256: Study to evaluate set time and strength of LiquiBand Exceed® (Advanced Medical Solutions/Covidien) Topical skin adhesive (TSA). August 13, 2015. Ethicon, Inc. 8. Keplinger S. Report: protocol to determine the strength benefits when adding DERAMBOND™ ADVANCED Topical Skin Adhesive to a wound or incision using suture as the primary closure. July 7, 2011. Ethicon, Inc. 9. Liquiband® Exceed™ Website. Advanced Medical Solutions Ltd. <http://www.liquiband.com/region/uk/liquiband-product-range-wound-closure/liquiband-exceed/> Accessed December 6, 2018. 10. Grimaldi L, et al. Octyl-2-cyanoacrylate adhesive for skin closure: eight years of experience. *In Vivo*. 2015;29(1):145-148. 11. Singer AJ, Perry LC, Allen Jr RL. In vivo study of wound-bursting strength and compliance of topical skin adhesives. *Acad Emerg Med*. 2008;15(12):1290-94. 12. Singer AJ, Perry L. A comparative study of the surgically relevant mechanical characteristics of the topical skin adhesives. *Acad Emerg Med*. 2012;19(11):1281-86. 13. Keplinger, S. Comparison of setting times of topical skin adhesive products. Report 11TR053. August 16, 2011. Ethicon, Inc. 14. Kumar A. AST\_2012\_0290: Completion report study to compare the tissue holding strength of PRINEO Skin Closure System with conventional wound closure techniques. October 2012. Ethicon, Inc.